Becton invests $3 million in Lucent:
This article was originally published in Clinica
Executive Summary
Becton Dickinson has acquired 19.9% of Lucent Medical. The Seattle-based Lucent is developing low-cost intelligent infusion therapy and surgical devices. Becton invested $3 million. Other companies putting money into Lucent in its second round of funding included JAFCO and Daiwa Business Investment, both of Tokyo. Previous investors include the University of Washington.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.